News

UroToday9h
ASCO 2025: Prognostic Utility of ctDNA Before and After Trimodality Therapy (TMT) for Muscle Invasive Bladder Cancer
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Kidney and ...
UroToday9h
ASCO 2025: Avelumab + Sacituzumab Govitecan versus Avelumab Monotherapy as First-Line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma: Interim Analysis ...
(UroToday.com) The 2025 ASCO annual meeting featured a urothelial carcinoma oral abstract session and a presentation by Dr. Jeannie Hoffman-Censits discussing an interim analysis from the JAVELIN ...
UroToday22h
ASCO 2025: Phase 3 AMPLITUDE Trial: Niraparib and Abiraterone Acetate plus Prednisone for Metastatic Castration-Sensitive Prostate Cancer Patients with Alterations in ...
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, IL, was host to the Oral Abstract Session: Genitourinary Cancer—Prostate, Testicular, and Penile.
UroToday22h
ASCO 2025: Multimodal Artificial Intelligence (MMAI) Model to Identify Benefit from 2nd-Generation Androgen Receptor Pathway Inhibitors (ARPI) in High-Risk Non-Metastatic ...
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Oral Abstract Session: Genitourinary Cancer—Prostate, Testicular, and Penile.
UroToday22h
ASCO 2025: Safety and Pharmacokinetics of Mevrometostat in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Prostate, ...
UroToday22h
ASCO 2025: Parp Up the Volume!: Combination Strategies in Advanced Prostate Cancer
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Oral Abstract Session: Genitourinary Cancer—Prostate, Testicular, and Penile.
UroToday22h
ASCO 2025: Discussion: Better Treatments, Better Selection: Improving Patient Outcomes in Localized Prostate Cancer
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Oral Abstract Session: Genitourinary Cancer—Prostate, Testicular, and Penile.